Understanding Non-Alcoholic Fatty Liver Disease: Prevalence, Risk Factors, and Innovative Treatment Approaches
OthersPage Navigation
Introduction
Non-Alcoholic Fatty Liver Disease (NAFLD) is a growing concern worldwide due to its increasing prevalence and potential for serious liver complications.
Prevalence
NAFLD affects approximately 25% of the global population, making it the most common form of chronic liver disease.
Risk Factors
Key risk factors include obesity, type 2 diabetes and dyslipidemia. Genetic predisposition also plays a significant role.
Innovative Treatment Approaches
While lifestyle changes remain the cornerstone of management, emerging therapies such as GLP-1 agonists and FXR agonists show promise.
Conclusion
Understanding NAFLD's prevalence, risk factors, and innovative treatments is crucial for effective management and patient care.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Immunotherapy and targeted radiation shrink liver tumors, enabling surgery
2.
Proton Therapy Fails to Beat IMRT in Prostate Cancer
3.
Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights
4.
Detecting pancreatic cancer through changes in body composition and metabolism
5.
In a clinical trial, "3D mammography" nearly reduces the incidence of breast cancer between two screening exams.
1.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
2.
The Benefits and Risks of Cervical Conization
3.
Unveiling the Hidden Causes of Anemia: A Comprehensive Look at a Common Condition
4.
Critical Care Updates on Hematopoietic Dysfunction During Prolonged Critical Illness
5.
Unlocking a New Era in Bladder Cancer Treatment: A Review of the TAR-200 Intravesical Drug Delivery System
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Managing Fatigue During Cancer Treatment
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge